A5004648803- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- Genetic factors in colorectal cancer
- Ferroptosis and cancer prognosis
- Esophageal Cancer Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Nanoplatforms for cancer theranostics
- HER2/EGFR in Cancer Research
- Lymphoma Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Diagnosis and Treatment
- Advanced biosensing and bioanalysis techniques
- Cancer-related Molecular Pathways
- Advanced Neuroimaging Techniques and Applications
- Advanced Breast Cancer Therapies
- Gastrointestinal Tumor Research and Treatment
- Galectins and Cancer Biology
- Neuroendocrine Tumor Research Advances
Immune checkpoint inhibitors (ICIs) are effective in the treatment of advanced esophageal squamous cell carcinoma (ESCC); however, their efficacy locally resectable ESCC and potential predictive biomarkers have limited data.In this study, patients were enrolled received neoadjuvant toripalimab (240 mg, day 1) plus paclitaxel (135 mg/m2, carboplatin (area under curve 5 mg/mL per min, each 3-week cycle for 2 cycles, followed by esophagectomy planned 4-6 weeks after preoperative therapy. The...
NOTCH signaling is associated with tumorigenesis, mutagenesis, and immune tolerance in non-small cell lung cancer (NSCLC), indicating its association the clinical benefit of checkpoint inhibitors (ICI). We hypothesized that mutation NSCLC might be a robust predictor immunotherapeutic efficacy.Multiple-dimensional data including genomic, transcriptomic, from cohorts internal public involving patients were analyzed. Polymorphism Phenotyping v2 (PolyPhen-2) system was performed to determine...
Background Postoperative circulation tumor DNA (ctDNA) is a promising method to predict the risk of recurrence. However, amount ctDNA in patients with early NSCLC too small. Cell damages caused during intraoperative period leads significant increase cell free (cfDNA). Whether cfDNA content restored preoperative level within short time after surgery may indicate degree surgical trauma. In this study, dynamic changes combined perioperative were used explore possibility them as biomarker...
The efficacy and safety of immunotherapy have been widely recognized in gastrointestinal-related cancers. However, the neoadjuvant camrelizumab for locally advanced esophageal squamous cell carcinoma (ESCC) has not firmly established. This study compared combination with DCF (docetaxel, cisplatin fluorouracil), alone ESCC, exploring biomarkers related to immune infiltration ESCC response.We enrolled randomly assigned patients stage II-IVa two treatments: combined docetaxel, fluorouracil...
Based on data analysis of 9649 Chinese primary NSCLC patients, we calculated the exact proportion EGFR subtypes in and evaluated TMB level, PD-L1 expression level tumor immune microenvironment among different mutation subtypes. Postoperative follow-up for 98 patients were collected analyzed. The results showed that several uncommon have a higher TMB-high or strong positive than total group. In addition, characteristics related to microenvironment, such as G719 mutations being associated with...
Purpose The human epidermal growth factor receptor 2 (HER2) is an established therapeutic target for various kinds of solid tumors. <i>HER2</i> amplification occurs in approximately 1% to 6% colorectal cancer. In this study, we aimed assess the efficacy and safety trastuzumab combination with chemotherapy HER2-positive metastatic cancer (mCRC).Materials Methods An open-label, phase II trial (Clinicaltrials.gov: NCT03185988) was designed evaluate antitumor activity digestive...
About one-third of nonsmall cell lung cancer (NSCLC) patients develop brain metastases (BM). However, there is an unmet need for early diagnosis and treatment BM. The precise mechanism BM still unknown. the genetic heterogeneity between primary tumor paired indicates that sampling from may not be able to fully represent mutational status in metastases. In this study, adenocarcinoma was analyzed.A total 11 samples tumors were included, which 7 finally analyzed. Samples sequenced by...
To explore the correlation between hepatocellular carcinoma (HCC) gene variation profile and clinical characteristics in Han nationality with HBV infection Sichuan province.The data HCC tissues were obtained from enrolled patients. Whole exome sequencing bioinformatics analysis performed on formalin-fixed paraffin-embedded samples HCC. Tumor mutational burden (TMB) was measured by an algorithm developed in-house.Sixteen high-frequency mutated genes differential expressions identified WES....
e21095 Background: Leptomeningeal metastasis (LM) indicates an unfavorable prognosis in non-small cell lung cancer (NSCLC). Due to the blood-brain barrier, plasma is not ideal medium evaluate osimertinib resistance mechanisms patients with LM. This study aimed use cerebrospinal fluid (CSF) as a source of ctDNA for characterizing molecular features and monitoring intracranial responses from leptomeningeal metastases who progressed on osimertinib. Methods: From Jan 2020 Nov 2022, 65 advanced...
Tumors can be caused by genetic or environmental factors, but previous studies have shown that factors contribute less to lung cancer than factors. The epidermal growth factor receptor (EGFR) is the most common driver gene in non-small-cell (NSCLC), variations are somatic. In this study, we reported on pedigree of EGFR p.V1010M germline mutation for first time, and explored correlation between V1010M occurrence NSCLC. Further, effect treatment EGFR-tyrosine kinase inhibitors (TKIs) was...
The human retinoblastoma susceptibility gene (RB1) is a tumor-suppressor mutated at different frequencies in many cancers. aim of the present study was to investigate distribution overall RB1 mutation and types range Chinese patients with solid tumors.We investigated mutations formalin-fixed, paraffin-embedded (FFPE) tissues cancer who underwent next-generation sequencing (NGS) 3DMed Clinical Laboratory Inc from January 1, 2017 April 15, 2020.Genomic alterations were identified 1,712 (7.6%)...
Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when develop resistance, there is currently no definite postosimertinib option. Herein, we report a patient metastatic NSCLC who benefited from almonertinib after developing resistance to osimertinib.
e20042 Background: In non-small cell lung cancer (NSCLC), more and driver fusions are suitable for targeted therapy. Sequential or parallel DNA RNA sequencing is an option, but it costly requires sufficiently high quality biopsy material. The purpose of this study was to confirm the consistency fusion genes detected by DNA-based NGS RNA-based in same sample, validate performance FFPE samples NGS. Methods: study, we evaluated benefits capture-based amplicon-based identifying gene...
Complete mesangectomy and central vascular detachment are the core elements of laparoscopic right hemicolectomy. Failure to identify variations in patients undergoing hemicolectomy can result unwanted bleeding, a prolonged surgical time, transfer open surgery, an elevated risk postoperative complications. In this case report, we describe new variation that has not yet been reported literature. Parallelly management vessels key areas essential for successful surgery.The patient was...
The treatment of lung cancer has fully entered the era immunotherapy, which significantly elevated survival rate patients with advanced non-small cell (NSCLC), thus shedding light on resectable NSCLC. Previous clinical trial data suggested that neoadjuvant immuno-chemotherapy obtained a significant objective response (ORR) and disease control (DCR). Here, case achieved an excellent outcome following was reported. patient admitted to our hospital 58 years old, female, rare stage IB squamous...
Abstract Background: Epidermal growth factor receptor (EGFR) mutation is regarded as a predictor for poor clinical response to immunotherapy in non-small cell lung cancer (NSCLC), which common EGFR mutations (the L858R point and exon 19 deletions) generally exist lower tumor burden (TMB) level. On the other side, uncommon variable efficacy tyrosine kinase inhibitors (TKIs) treatment these patients still controversial. Therefore, we conducted this study investigate correlation between TMB....
Abstract Background: Distant metastasis accounts for ~90% of deaths from colorectal cancer (CRC). The use biomarkers targeted therapy in metastatic CRC is well-established, requiring genetic testing primary or biopsies. Here we aimed to assess the concordance actionable alterations matched and tumors. Methods: Hybrid capture-based next-generation sequencing (NGS) were performed a CAP/CLIA-approved laboratory (3DMed). NGS SNV, InDel, CNV, MSI TMB on 19 tumors 23 Results: 42 tumor samples...